The National Platform for Physical AI Oncology Trials represents a paradigm shift in how oncology clinical trials are regulated, conducted, and scaled. Physical AI, defined as the integration of embodied robotic systems with advanced artificial intelligence for direct patient care in clinical trial settings, offers a transformative path to treat significantly more patients at lower cost and higher quality than traditional human-only trial operations.
Kevin Kawchak (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: